Vaginorm (dehydroepiandrosterone) / Endoceutics, Bayer, Millicent Pharma - LARVOL DELTA

Prasterone for vulvar and vaginal atrophy in postmenopausal women. (PubMed, Aust Prescr) - No abstract available

Journal • Review • Vaginal Atrophy • Women's Health

A Clinical Study of INTRAROSA® (Prasterone) Vaginal Inserts in Postmenopausal Vulvovaginal Atrophy (clinicaltrials.gov) - P3 | N=417 | Completed | Sponsor: Lee's Pharmaceutical Limited | Active, not recruiting ➔ Completed

Trial completion • Vaginal Atrophy • Women's Health

Dehydroepiandrosterone and Its Metabolite 5-Androstenediol: New Therapeutic Targets and Possibilities for Clinical Application. (PubMed, Pharmaceuticals (Basel)) - "At present, the clinical use of dehydroepiandrosterone is limited by its Intrarosa® (Quebec city, QC, Canada) prasterone) 6.5 mg vaginal suppositories for the treatment of vaginal atrophy and dyspareunia, while the dehydroepiandrosterone synthetic derivatives Triplex, BNN 27, and Fluasterone have the investigational status for the treatment of various diseases...The design and synthesis of new 5-androstenediol derivatives with increased bioavailability may lead to the appearance of highly effective cytoprotectors on the pharmaceutical market. The argumentations for new clinical applications of these steroids and novel insights into their mechanisms of action are discussed."

Journal • Review • Cachexia • Osteoporosis • Rheumatology • Sarcopenia • Vaginal Atrophy • Women's Health

Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors (clinicaltrials.gov) - P2 | N=8 | Terminated | Sponsor: University of Arkansas | N=60 ➔ 8 | Trial completion date: Jun 2025 ➔ Jul 2023 | Recruiting ➔ Terminated | Trial primary completion date: Jun 2024 ➔ Jul 2023; Low recruitment/enrollment

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Vaginal Atrophy • Women's Health • HER-2

Drugs for menopausal symptoms. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal

A Clinical Study of Intravaginal Prasterone (Intrarosa®) in Postmenopausal Vulvovaginal Atrophy (clinicaltrials.gov) - P3 | N=418 | Active, not recruiting | Sponsor: Lee's Pharmaceutical Limited | Not yet recruiting ➔ Active, not recruiting | Trial primary completion date: Sep 2022 ➔ Jan 2023

Enrollment closed • Trial primary completion date • Vaginal Atrophy • Women's Health

Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors (clinicaltrials.gov) - P2; N=60; Recruiting; Sponsor: University of Arkansas; Not yet recruiting ➔ Recruiting; Trial completion date: Aug 2023 ➔ Jun 2024; Trial primary completion date: Aug 2022 ➔ Jun 2023

Clinical • Enrollment open • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Vaginal Atrophy • Women's Health • HER-2

Changes to Vulva, Vestibule, Urethral Meatus and Vagina 20 Weeks Post Daily Prasterone in Women With Dyspareunia (clinicaltrials.gov) - P4 | N=18 | Completed | Sponsor: San Diego Sexual Medicine | Recruiting ➔ Completed

Trial completion

Beneficial Effects of Intrarosa® (Vaginal Prasterone) on the Vaginal Histology of Women with VVA Treated or not with Aromatase Inhibitors: A Breakthrough in the Understanding of the Role of Androgens in Vaginal Health. (ISGE 2022) - "Conclusions Although there is some level of clinical evidence in the literature suggesting that androgens can help treat symptoms of the genitourinary syndrome of menopause (GSM), data presented here are believed to be the first demonstration of profound beneficial effects of androgens on VVA, independently from estrogens. While further studies are warranted to better understand the respective contributions of androgens and estrogens to the benefits observed with prasterone in the treatment of GSM, the data presented here strongly suggests that androgens play a significant role in the physiopathology of VVA."

Clinical • Breast Cancer • Oncology • Solid Tumor • Vaginal Atrophy • Women's Health

VIBRA: Vaginal Prasterone In Vaginal Atrophy In Breast Cancer Survivors (clinicaltrials.gov) - P4 | N=10 | Completed | Sponsor: Hospital Clinic of Barcelona | Recruiting ➔ Completed | Trial primary completion date: Feb 2021 ➔ Nov 2021

Trial completion • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor • Vaginal Atrophy • Women's Health

"Theramex Australia Enters Partnership With Endoceutics For Intrarosa® For The Treatment Of Postmenopausal Vulvovaginal Atrophy https://t.co/Gu6WnoqobQ" (@NewsFromBW)

Licensing / partnership • Vaginal Atrophy • Women's Health

A Clinical Study of Intravaginal Prasterone (Intrarosa®) in Postmenopausal Vulvovaginal Atrophy (clinicaltrials.gov) - P3; N=418; Not yet recruiting; Sponsor: Lee's Pharmaceutical Limited

New P3 trial • Vaginal Atrophy • Women's Health

Clinical Trial on the Preventive Effect of Intravaginal Prasterone on Recurrent Urinary Tract Infections in Postmenopausal Women (clinicaltrials.gov) - P3; N=0; Withdrawn; Sponsor: Olivia Cardenas-Trowers, M.D.; N=58 ➔ 0; Not yet recruiting ➔ Withdrawn

Clinical • Enrollment change • Trial withdrawal • Infectious Disease • Nephrology • Women's Health

Modern management of genitourinary syndrome of menopause. (PubMed, Fac Rev) - "Today, women are spending 40% of their lives in the postmenopausal state, and with 50-70% of postmenopausal women reporting symptomatic GSM, safe and efficacious treatments are needed for this troublesome condition. This article reviews current evidence for non-pharmacological and pharmacological treatments with a focus on novel and minimally invasive procedures such as energy-based devices (CO laser, YAG laser), hyaluronic acid, dehydroepiandrosterone, and selective oestrogen receptor modulators."

Journal • Review

Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors (clinicaltrials.gov) - P2; N=60; Not yet recruiting; Sponsor: University of Arkansas; Trial completion date: Aug 2022 ➔ Aug 2023; Initiation date: Dec 2020 ➔ May 2021; Trial primary completion date: Aug 2021 ➔ Aug 2022

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor • Vaginal Atrophy